Along with more potential clinical studies and validation, molecular imaging of HER2-positive and MUC1-positive breast cancer could allow patient-customized dosage adaptation, with early finishing of ineffective and expensive therapies and reduction of “aggressive” treatment, ultimately resulting in cost savings, lower morbidity, and improved patient outcomes. The gene discussed is ERBB2; the disease is breast cancer.